B. Perrucci

发表

Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study

B. Delahunt, C. Porta, M. Fassan, 2022, Journal of personalized medicine.

Safety and Efficacy of Dose-dense Chemotherapy with TCF Regimen in Elderly Patients with Locally Advanced or Metastatic Gastric Cancer

R. Passalacqua, M. Martinotti, G. Tomasello, 2017, Tumori.

Delivery of Cancer Care at Home during the First COVID-19 Pandemic in Italy: A Case Series Study (DomOnCOVID Project)

F. Crea, C. Caminiti, F. Diodati, 2021, Clinical Oncology and Research.

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

A. Marchetti, F. Buttitta, S. Iacobelli, 2009, Neoplasia.

MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma

C. Porta, F. Alongi, M. Milella, 2020, Journal of Clinical Pathology.

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.

M. Nicoloso, S. Pignata, G. de Matteis, 2023, The Lancet. Oncology.

Diagnostic use of contrast medium and the kidney: A challenge or a ghost?

F. Malberti, S. Panni, M. Foramitti, 2018 .

2639 Effectiveness and possible Molecular factors predictive of clinical Outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: A multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)

G. Ceresoli, R. Montironi, S. Pignata, 2015 .

Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant forHER2-mutant, hormone receptor-positive, metastatic breast cancer

S. Loi, M. Burkard, H. Wildiers, 2021 .

Tyrosine kinase inhibitors.

S. Iacobelli, F. Perrotti, L. Falchi, 2010, Current Cancer Drug Targets.

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)

C. De Marco, U. de Giorgi, G. Procopio, 2024, Therapeutic advances in medical oncology.